文献速递精神分裂症与精神病性障碍

基于影像的生物标志物在精神病性障碍谷氨酸靶向药物开发中的效用:一项随机临床试验

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

该随机临床试验在健康志愿者中比较氯胺酮与安慰剂对三种影像学谷氨酸靶点Engagement生物标志物的影响,发现药理学BOLD信号效应量极大且跨站点一致,1H MRS信号较小但显著,任务态fMRI无显著组间差异。结论支持药理学BOLD作为跨站点功能靶点Engagement的确证性评估工具,其他指标虽敏感但稳健性不足。

要点

  • 药理学BOLD检测到氯胺酮诱导的fMRI反应高度稳健增加(Cohen d=5.4;P<.001),跨站点一致。
  • 1H MRS测定的谷氨酸+谷氨酰胺水平在氯胺酮输注后立即出现较小但显著信号(Cohen d=0.64;P=.04)。
  • 任务态fMRI激活反应未发现组间显著差异,不支持其作为跨站点靶点Engagement指标。

核心结论

  • 氯胺酮对药理学BOLD具有跨站点稳健效应,支持其用于功能靶点Engagement的确证性评估。
  • 其他指标虽对氯胺酮效应敏感,但稳健性不足以作为跨站点靶点Engagement测量工具。

研究设计与样本

  • 随机临床试验在学术研究机构开展,招募18至55岁无显著躯体或精神疾病史的健康志愿者,来自3个站点。
  • 志愿者接受序贯氯胺酮输注(0.23 mg/kg输注1分钟,继以0.58 mg/kg/h输注30分钟,再以0.29 mg/kg/h输注29分钟)或安慰剂输注。
  • 所有评定者对研究分组盲法,主要结局为氯胺酮诱导的药理学BOLD、1H MRS和任务态fMRI指标变化及症状评分。

主要发现

  • 65名志愿者中41名(63%)为男性,平均(SD)年龄31.1(9.6)岁;59名(91%)至少有一次有效扫描;53名(82%)完成两次氯胺酮输注。
  • 药理学BOLD显示fMRI反应高度稳健增加(Cohen d=5.4;P<.001),且各站点反应一致。
  • 1H MRS测定的谷氨酸+谷氨酰胺水平在氯胺酮输注后立即出现较小但显著信号(Cohen d=0.64;P=.04)。
  • 任务态fMRI激活反应未发现组间显著差异。

关键数值与推荐

  • 药理学BOLD组效应量Cohen d=5.4,P<.001,跨站点一致。
  • 1H MRS组效应量Cohen d=0.64,P=.04。
  • 任务态fMRI组间无显著差异。

临床怎么用

  • 在早期临床研究中,药理学BOLD可作为谷氨酸能靶点Engagement的跨站点生物标志物用于确证性评估。
  • 1H MRS和任务态fMRI虽对氯胺酮效应敏感,但稳健性不足,不宜作为跨站点靶点Engagement指标。

局限性

  • 研究仅纳入健康志愿者,未在精神病性障碍患者中验证。
  • 样本量有限,且部分志愿者未完成全部扫描或输注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite strong theoretical rationale and preclinical evidence, several glutamate-targeted treatments for schizophrenia have failed in recent pivotal trials, prompting questions as to target validity, compound inadequacy, or lack of target engagement. A key limitation for glutamate-based treatment development is the lack of functional target-engagement biomarkers for translation between preclinical and early-stage clinical studies. We evaluated the utility of 3 potential biomarkers-ketamine-evoked changes in the functional magnetic imaging (fMRI) blood oxygen level-dependent response (pharmacoBOLD), glutamate proton magnetic resonance spectroscopy (1H MRS), and task-based fMRI-for detecting ketamine-related alterations in brain glutamate. OBJECTIVE: To identify measures with sufficient effect size and cross-site reliability to serve as glutamatergic target engagement biomarkers within early-phase clinical studies. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted at an academic research institution between May 2014 and October 2015 as part of the National Institute of Mental Health-funded Fast-Fail Trial for Psychotic Spectrum Disorders project. All raters were blinded to study group. Healthy volunteers aged 18 to 55 years of either sex and free of significant medical or psychiatric history were recruited from 3 sites. Data were analyzed between November 2015 and December 2016. INTERVENTIONS: Volunteers received either sequential ketamine (0.23 mg/kg infusion over 1 minute followed by 0.58 mg/kg/h infusion over 30 minutes and then 0.29 mg/kg/h infusion over 29 minutes) or placebo infusions. MAIN OUTCOMES AND MEASURES: Ketamine-induced changes in pharmacoBOLD, 1H MRS, and task-based fMRI measures, along with symptom ratings. Measures were prespecified prior to data collection. RESULTS: Of the 65 volunteers, 41 (63%) were male, and the mean (SD) age was 31.1 (9.6) years; 59 (91%) had at least 1 valid scan. A total of 53 volunteers (82%) completed both ketamine infusions. In pharmacoBOLD, a highly robust increase (Cohen d = 5.4; P < .001) in fMRI response was observed, with a consistent response across sites. A smaller but significant signal (Cohen d = 0.64; P = .04) was also observed in 1H MRS-determined levels of glutamate+glutamine immediately following ketamine infusion. By contrast, no significant differences in task-activated fMRI responses were found between groups. CONCLUSIONS AND RELEVANCE: These findings demonstrate robust effects of ketamine on pharmacoBOLD across sites, supporting its utility for definitive assessment of functional target engagement. Other measures, while sensitive to ketamine effects, were not sufficiently robust for use as cross-site target engagement measures. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02134951.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Javitt DC, Carter CS, Krystal JH, et al. Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 29167877. doi:10.1001/jamapsychiatry.2017.3572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。